A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Clinical trial NCT02504645 · COMPLETED
Trial details
- NCT number
- NCT02504645
- Sponsor
- ImmuPharma
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-01
- Primary completion
- 2018-01-01
- Enrollment
- 202
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.